ZURICH. The Swiss Market Index closed on Thursday at a record 14,756.86, up 1.21 per cent, and the session high went further still. The intraday peak was 14,861.53. The previous closing landmark, set in August at 14,670, did not survive the afternoon. The index could not hold 14,800 into the bell. It did not need to. Seventeen of the twenty SMI names finished higher.
The money that got it there is leaving a different market. Traders described a rotation out of technology shares and into companies that still sell when growth slows. Switzerland is built for that trade. Pharmaceuticals and food carry an unusual weight in the SMI, and those businesses do not need a boom to keep customers. The franc had already held near 0.83 after the Federal Reserve left rates unchanged. Thursday’s equity rally was the same mood, expressed in shares rather than in the currency.
Novartis did the heavy lifting
Novartis rose 2.4 per cent to CHF 132.30 and printed a record of its own. Dealers pointed to a JPMorgan target raised to CHF 145. Roche added 0.7 per cent. Nestlé, higher in the morning, finished unchanged. Together the three still decide whether the SMI has a good day. That concentration is the complaint that arrives in the same breath as the celebration: a benchmark this narrow is a bet on three companies wearing the costume of a market.
The broad market came along, at a calmer pace. The SPI rose 1.01 per cent to 20,793.53. The mid-cap SMIM gained 0.22 per cent to 3,200.13. This was a large-cap day. It was also a Swiss day in a European one. Major European markets advanced. Wall Street did not.
The rates that did not move
Neither the Federal Reserve nor the European Central Bank touched its policy rate this week. That was the forecast, and it was enough. American growth in the third quarter came in faster than expected, which on some desks now argues for a rise in December, and a similar debate has started around the ECB. One line in the Zurich market was that if energy-driven price pressure lasts, a move to 2.75 per cent in the euro area in December is likely. Brent crude still fell by nearly 1.5 per cent into the European close and remains above 113 dollars a barrel. Oil is no longer climbing every day. It is not cheap.
Christine Lagarde’s early departure, set for February 2027, added a second Frankfurt question the Swiss market cannot answer. A change at the top of the ECB is not a Swiss earnings story. It is a rates story, and rates are what have been pushing investors toward the defensive names Zurich already lists.
One sharp fall, and a bank in the bid
Amrize was the clear loser while the index was making its morning high, down just over 5 per cent after disappointing quarterly figures and a cut to its full-year forecast. The contrast is the point of a record day. An index can close at an all-time high while a cyclical name is being marked down for saying the year will be worse.
UBS, a session after a $2.7 billion quarterly profit and a buyback brought forward to February, was among the supports into the close. The capital argument in Bern is unchanged by a record SMI. What Thursday showed is where global money goes when it wants out of the technology trade and still wants a market that opens. For the moment, that market is this one.